IntelGenx Technologies (IGXT) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
IntelGenx Technologies reports promising preliminary results from its Phase 2a BUENA study on Montelukast VersaFilm® for treating mild to moderate Alzheimer’s disease, with a higher dose showing significant cognitive improvement. Despite overall mixed results, the 30-mg twice-daily dose of the buccal film demonstrated a notable benefit, prompting further research. The Alzheimer’s market is projected to grow substantially, indicating a strong potential for new therapies like IntelGenx’s repurposed Montelukast.
For further insights into IGXT stock, check out TipRanks’ Stock Analysis page.